All In Biotech

Free tool

FAERS Monitor: Ryzneuta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761134 or its brand name (Ryzneuta, Efbemalenograstim Alfa-Vuxw). Reports on generic versions are filed under their own applications.

Reports

45

Serious

45

100% of reports

Hospitalization

23

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • anaphylactic shock11
  • asthenia8
  • dizziness7
  • chest discomfort5
  • dyspnoea5
  • nausea5
  • hyperhidrosis4
  • pyrexia4
  • white blood cell count increased4
  • blood pressure decreased3
  • myelosuppression3
  • neutrophil count decreased3
  • neutrophil count increased3
  • oxygen saturation decreased3
  • pallor3

Reports by year received

View as table
YearReports
20246
202517
202622

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,114 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
anaphylactic shockSignal11199.6119.41,981
neutrophil count increasedSignal3137.045.9280
pallorSignal351.517.3103
white blood cell count increasedSignal448.719.1143
myelosuppressionSignal338.913.076
neutrophil count decreasedSignal334.411.567
oxygen saturation decreasedSignal325.08.447
chest discomfortSignal522.810.084
blood pressure decreasedSignal321.17.139
hyperhidrosisSignal414.55.738
astheniaSignal89.95.357
dizzinessSignal76.63.328
pyrexiaSignal45.42.110
dyspnoeaSignal54.11.89
nauseaSignal53.01.35

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.